The current price of LBRX is $38.09 — it has decreased by 6.76% since the previous close. Data as of Nov 5, 2026.
LBRX is down 5.01% over the past week, up 10.02% over the past month and up 135.12% over the past year. The price is above its 200-day moving average of $32.86.
Analysts' average 12-month price target for LBRX is $59.78, which implies 56.94% upside from the current price. Individual estimates range from $35.00 to $80.00.
Of the 11 analysts covering LB Pharmaceuticals Inc Common Stock, 2 rate it a strong buy, 8 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
LB Pharmaceuticals Inc Common Stock has a market capitalization of $1.23B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, LB Pharmaceuticals Inc Common Stock posted a loss of $1.71 per share against an estimate of -$0.8037, missing expectations by 112.78%. Upcoming reports are listed in the earnings calendar.
Companies most comparable to LB Pharmaceuticals Inc Common Stock include Definium Therapeutics, Inc., Acadia Pharmaceuticals Inc., Denali Therapeutics Inc., GH Research PLC and Rapport Therapeutics, Inc. Common Stock.
In the latest trading session LBRX moved between $38.03 and $41.01, a range of 7.82% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of LB Pharmaceuticals Inc Common Stock shows a sell rating today and a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks LBRX has traded between $14.32 and $50.16. The current price is 24.06% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.